Literature DB >> 25968636

Non-hormonal treatment of vulvo-vaginal atrophy-related symptoms in post-menopausal women.

C Tersigni1, N Di Simone1, E Tempestilli1, F Cianfrini2, R Russo2, M C Moruzzi1, I D Amar1, A Fiorelli1, G Scambia1, P Villa1.   

Abstract

In post-menopausal period vulvo-vaginal atrophy (VVA)-related symptoms may seriously affect women's quality of life. Hormonal replacement therapy effectively relieves these symptoms but it is not always safe or accepted, and a non-hormonal treatment is often needed instead. Over a period of 12 weeks, we tested the effect of a twice-a-week vulvo-vaginal application of a hyaluronic acid, AC collagen, isoflavones and vitamins-based cream (Perilei Pausa) on 35 women in post-menopausal period, reporting VVA-related symptoms. After 12 weeks of treatment with Perilei Pausa a significant improvement in vaginal dryness, vulvo-vaginal itching, dyspareunia (P < 0.001), dysuria (P = 0.02), nocturia (P = 0.009) and pollakiuria (P = 0.005) was reported by the women. Colposcopical score assessing the intensity of atrophic colpitis, cervico-vaginal paleness and petechiae was also reduced (P = 0.037, P = 0.016 and P = 0.032, respectively). No significant difference in terms of maturation value of cervico-vaginal epithelium was observed. In conclusion, Perilei Pausa may represent an effective and safe alternative treatment of symptomatic VVA in post-menopausal women.

Entities:  

Keywords:  collagen; dyspareunia; hyaluronic acid; isoflavones; vulvo-vaginal atrophy

Mesh:

Substances:

Year:  2015        PMID: 25968636     DOI: 10.3109/01443615.2015.1014326

Source DB:  PubMed          Journal:  J Obstet Gynaecol        ISSN: 0144-3615            Impact factor:   1.246


  1 in total

1.  Topical treatment of vaginal dryness with a non-hormonal cream in women undergoing breast cancer treatment - An open prospective multicenter study.

Authors:  Dimitrios Chatsiproios; Iris M Schmidts-Winkler; Lisa König; Clarissa Masur; Christoph Abels
Journal:  PLoS One       Date:  2019-01-24       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.